Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden clots in heart failure? new study tests routine screening

NCT ID NCT07499661

Diagnosis Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether blood clots in the lungs (pulmonary embolism) are often missed in people hospitalized with acute heart failure. About 740 patients across multiple hospitals will take part. In half the hospitals, doctors will follow their usual approach; in the other half, they will systematically test every patient for a clot using a standard diagnostic checklist. The goal is to see if routine testing leads to more diagnoses and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Systematic diagnostic algorithm for pulmonary embolism (including Geneva score, D-dimer testing, and imaging)
What this could lead to
If successful, this could show that routine screening for blood clots in the lungs is worthwhile for all patients hospitalized with acute heart failure, leading to earlier treatment and fewer complications.
What could go wrong
This is a pragmatic trial testing a diagnostic strategy, not a new treatment. The expected increase in detection is modest (from 1% to 5%), and it may not translate into better survival or fewer hospital readmissions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 740 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (≥18 years) * Admission to the emergency department or cardiology unit of a participating center * Recent onset or worsening dyspnea and/or orthopnea * Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following: * Bilateral pulmonary crackles on auscultation and/or peripheral edema * Signs of pulmonary congestion on chest X-ray or lung/cardiac ultrasound * Elevated natriuretic peptide levels (BNP or NT-proBNP) * Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure) * Patient affiliated with or beneficiary of a social security system * Patient able and willing to provide free, informed, and written consent Exclusion Criteria: * Shock state suggesting cardiogenic shock and/or severe pulmonary embolism * Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations * Evidence of acute coronary syndrome on electrocardiogram at admission * Severe renal impairment (creatinine clearance \<30 mL/min) * Known hypersensitivity or allergy to iodinated contrast agents * Ongoing therapeutic anticoagulation for more than 48 hours prior to admission * Hospitalization for more than 48 hours prior to inclusion * Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable) * Inadequate understanding of the French language preventing proper study information and consent * Pregnant, breastfeeding, or postpartum women * Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease heart failure pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF) Pulmonary embolism (diagnosis) Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Agen Hospital, Emergency department

    NOT_YET_RECRUITING

    Agen, 47923, France

  • Angers University Hospital, Emergency Department

    RECRUITING

    Angers, 49000, France

  • Brest University Hospital (site Cavale Blanche), Cardiology Department

    NOT_YET_RECRUITING

    Brest, 29200, France

  • Cholet Hospital, Emergency Department

    NOT_YET_RECRUITING

    Cholet, 49300, France

  • Clermont-Ferrand University Hospital, Emergency Department

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • Grenoble Alpes University Hospital, Adult Emergency Department

    NOT_YET_RECRUITING

    La Tronche, 38700, France

  • Lyon University Hospital (site Edouard Herriot), Emergency Department

    NOT_YET_RECRUITING

    Lyon, 69003, France

  • Poitiers University Hospital, Emergency Department

    NOT_YET_RECRUITING

    Poitiers, 86000, France

  • Toulouse University Hospital, Emergency Department

    NOT_YET_RECRUITING

    Toulouse, 31000, France

  • Tours University Hospital (site Trousseau), Adult Emergency Department

    NOT_YET_RECRUITING

    Chambray-lès-Tours, 37170, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.